This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/resource/domain/vavai/projekt/
n20http://linked.opendata.cz/resource/domain/vavai/subjekt/
n19http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n17http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F13%3A00068000%21RIV14-MSM-14110___/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F13%3A00068000%21RIV14-MSM-14110___
rdf:type
skos:Concept n19:Vysledek
dcterms:description
PURPOSE Existing ways of assessing CVID patients at risk of pulmonary infections are not universally accepted. The need to identify additional prognostic factors allowed us to evaluate the anti-polysaccharide IgA and IgM responses in 125 CVID patients immunized with the 23-valent pneumococcal polysaccharide (PS) vaccine (Pneumovax). RESULTS Anti-PS23 IgM and/or IgA antibodies were detectable in a minority of CVID patients. Antibody responses were correlated to B cell subpopulations and serum immunoglobulin concentrations. The non responders had a higher incidence of pneumonia and bronchiectasis and responders had the lowest incidence of respiratory complications. CONCLUSIONS This new ELISA assay allows for studying vaccine response in patients on Ig replacement therapy. This test also is an additional method of evaluation of specific antibody responses representing a valuable contribution to identify prognostic marker in CVID patients. PURPOSE Existing ways of assessing CVID patients at risk of pulmonary infections are not universally accepted. The need to identify additional prognostic factors allowed us to evaluate the anti-polysaccharide IgA and IgM responses in 125 CVID patients immunized with the 23-valent pneumococcal polysaccharide (PS) vaccine (Pneumovax). RESULTS Anti-PS23 IgM and/or IgA antibodies were detectable in a minority of CVID patients. Antibody responses were correlated to B cell subpopulations and serum immunoglobulin concentrations. The non responders had a higher incidence of pneumonia and bronchiectasis and responders had the lowest incidence of respiratory complications. CONCLUSIONS This new ELISA assay allows for studying vaccine response in patients on Ig replacement therapy. This test also is an additional method of evaluation of specific antibody responses representing a valuable contribution to identify prognostic marker in CVID patients.
dcterms:title
Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency
skos:prefLabel
Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency
skos:notation
RIV/00216224:14110/13:00068000!RIV14-MSM-14110___
n19:predkladatel
n20:orjk%3A14110
n4:aktivita
n13:P
n4:aktivity
P(7E08062)
n4:cisloPeriodika
4
n4:dodaniDat
n7:2014
n4:domaciTvurceVysledku
n18:3198391
n4:druhVysledku
n14:J
n4:duvernostUdaju
n10:S
n4:entitaPredkladatele
n9:predkladatel
n4:idSjednocenehoVysledku
101190
n4:idVysledku
RIV/00216224:14110/13:00068000
n4:jazykVysledku
n16:eng
n4:klicovaSlova
Common variable immunodeficiencies; anti-pneumococcal polysaccharide IgM; anti-pneumococcal polysaccharide IgA; ELISA; pneumonia; bronchiectasis
n4:klicoveSlovo
n6:anti-pneumococcal%20polysaccharide%20IgM n6:anti-pneumococcal%20polysaccharide%20IgA n6:Common%20variable%20immunodeficiencies n6:pneumonia n6:bronchiectasis n6:ELISA
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[B3A72673F30E]
n4:nazevZdroje
JOURNAL OF CLINICAL IMMUNOLOGY
n4:obor
n5:EC
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
11
n4:projekt
n15:7E08062
n4:rokUplatneniVysledku
n7:2013
n4:svazekPeriodika
33
n4:tvurceVysledku
Warnatz, K. Dräger, R. Quinti, I. Cavaliere, F. M. Milito, C. Schütz, K. Martini, H. Brunetti, G. Thon, Vojtěch Schlesier, M. Pesce, A. M.
n4:wos
000323125100015
s:issn
0271-9142
s:numberOfPages
9
n17:doi
10.1007/s10875-012-9856-z
n8:organizacniJednotka
14110